RCEL trades 14.9% above Wall Street's consensus target of $14.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes RCEL achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 19, 2026, Avita Medical Inc. (RCEL) has a Wall Street consensus price target of $14.33, based on estimates from 8 covering analysts. With the stock currently trading at $16.83, this represents a potential downside of -14.9%. The company has a market capitalization of $418M.
Analyst price targets range from a low of $11.00 to a high of $20.00, representing a 63% spread in expectations. The median target of $12.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, RCEL trades at a trailing P/E of -14.4x. Analysts expect EPS to grow +22.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
XTNTXtant Medical Holdings, Inc. | $29M | $0.21 | — | — | — | — | — |
TELATELA Bio, Inc. | $35M | $0.78 | — | — | — | — | — |
MDXGMiMedx Group, Inc. | $464M | $3.18 | $7.50 | +135.8% | Buy | — | 15 |
NVCRNovocure Ltd | $1.2B | $10.73 | $26.00 | +142.3% | Buy | — | 15 |
APYXApyx Medical Corporation | $105M | $2.49 | $6.50 | +161.0% | Buy | — | 9 |
ANGOAngioDynamics, Inc. | $468M | $11.32 | $19.00 | +67.8% | Hold | — | 11 |
SYKStryker Corporation | $122.0B | $318.15 | $354.47 | +11.4% | Buy | 21.4x | 52 |
BSXBoston Scientific Corporation | $64.9B | $43.64 | $54.65 | +25.2% | Buy | 13.8x | 44 |
ZBHZimmer Biomet Holdings, Inc. | $20.0B | $103.32 | $109.11 | +5.6% | Hold | 12.1x | 42 |
MMSIMerit Medical Systems, Inc. | $5.1B | $85.93 | $107.33 | +24.9% | Buy | 19.7x | 15 |
Quick answers to the most common questions about buying RCEL stock.
RCEL's consensus price target is $14.33, -14.9% below the current price of $16.83. The 8 analysts tracking RCEL see downside risk at present valuations.
RCEL has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $14.33 implies -14.9% downside from current levels.
RCEL's current price is $16.83 with a consensus target of $14.33 (-14.9% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $20 for RCEL, while the most conservative target is $11. The consensus of $14.33 represents the median expectation. These targets typically reflect 12-month expectations.
RCEL is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RCEL stock forecast based on 8 Wall Street analysts shows a consensus price target of $14.33, with estimates ranging from $11 (bear case) to $20 (bull case). The median consensus rating is "Buy".
Analysts are cautious on RCEL, with 0 Sell ratings and a price target of $14.33 (-14.9% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RCEL analyst price targets range from $11 to $20, a 63% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $14.33 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.